Discounted Cash Flow
Outset Medical, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $15.1m | $-68.3m | $-73.6m | -453.0% | — |
| 2020 | $49.9m (231.2%) | $-121.5m (-77.9%) | $-108.1m (-46.9%) | -243.3% (46.3%) | — |
| 2021 | $102.6m (105.5%) | $-131.9m (-8.6%) | $-133.4m (-23.4%) | -128.6% (47.1%) | — |
| 2022 | $115.4m (12.4%) | $-163.0m (-23.5%) | $-154.1m (-15.5%) | -141.2% (-9.8%) | $-3.38 |
| 2023 | $130.4m (13.0%) | $-172.8m (-6.0%) | $-134.8m (12.5%) | -132.5% (6.2%) | $-3.48 (-3.0%) |
| 2024 | $113.7m (-12.8%) | $-128.0m (25.9%) | $-117.2m (13.1%) | -112.6% (15.1%) | $-2.46 (29.3%) |
| 2025 | $119.5m (5.1%) | $-81.7m (36.2%) | $-47.1m (59.8%) | -68.3% (39.3%) | $-5.37 (-118.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.